1 / 2

Impact de la génomique sur le choix de traitement néo-adjuvant : essai REMAGUS 04 (1)

Impact de la génomique sur le choix de traitement néo-adjuvant : essai REMAGUS 04 (1). Biopsy. Schéma de l’essai. ARM A Standard Arm 4 FEC 100 4 Docetaxel D1=D21. Adenocarcinoma of the breast cancer not eligible for breast conserving Surgery. Eligibility criteria met

marnie
Download Presentation

Impact de la génomique sur le choix de traitement néo-adjuvant : essai REMAGUS 04 (1)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Impact de la génomique sur le choix de traitement néo-adjuvant : essai REMAGUS 04 (1) Biopsy Schéma de l’essai ARM A Standard Arm 4 FEC 100 4 Docetaxel D1=D21 Adenocarcinoma of the breast cancer not eligible for breast conserving Surgery Eligibilitycriteria met for the trial and Genomic Test available Wholegenomearray Affymetrix U133Av2 Randomization Surgery pCR Lymphnode status ARM B Group B2 DLD30+: 12 weeklyPaclitaxel 4 FEC ClinicalEligibilitycriteria• HER2 negative• No multifocality• cT1-cT3 tumor• No metastases• Normal lab value• LVEF > 50% • SampleEligibilitycriteria• 30% cancer cells• RIN > 6• RNA content > 2 μg + DLD30 Group B3 DLD30-/TOP2A+: 4 FEC 4 Docetaxel - TOP2A > 500 (sensitive to anthracyclines) + TOP2A Groupe B4 DLD30-/TOP2A-: 6 Docetaxel + capecitabine - ESMO 2012 - D’après Pierga JY et al., abstr. 245O actualisé

  2. Impact de la génomique sur le choix de traitement néo-adjuvant : essai REMAGUS 04 (2) Réponses histologiques complètes selon le bras de traitement • The trial, designed to include 300 pts, wasstoppedafter a preplannedinterimanalysisshowing < 2 pathological Complete Response (pCR) out of 20in the DocetaxelCapecitabine Group (B4) ESMO 2012 - D’après Pierga JY et al., abstr. 245O actualisé

More Related